MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
Let’s be real: cannabis culture in 2026 looks nothing like it did even a decade…
A first-person review of the hemp-derived THC cocktail base I poured at our Cannabis Cup…
Every paper mill in the world still runs on the continuous-web design a Frenchman patented…
A new AI-assisted sci-fi satire from filmmaker Dan Levy Dagerman and the Space Weed Universe…
Spain has increased penalties for electricity theft linked to indoor cannabis cultivation after Endesa reported…
How a 52-year-old first-time grower turned trial and error into a show-stopping harvest The first…